Positive Phase III top-line results for Endo/BDSI pain drug; milestone triggered
This article was originally published in Scrip
Endo Pharmaceuticals and BioDelivery Sciences' (BDSI) have released positive top-line Phase III data for chronic pain drug BEMA buprenorphine, triggering a $10m milestone payment to the latter firm.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.